No Treatment Required
This patient does not require antiviral treatment for hepatitis C because they do not have evidence of current HCV infection. 1
Interpretation of Test Results
Your patient has:
- Reactive HCV antibody (positive)
- Undetectable HCV RNA (not detected)
This combination indicates either:
- Past resolved HCV infection (spontaneous or treatment-related clearance)
- Rarely, a false-positive antibody result
The absence of detectable HCV RNA definitively rules out active hepatitis C infection. 1 Without viremia, there is no virus to treat, and antiviral therapy is neither indicated nor beneficial.
Clinical Management
Immediate Actions
- Inform the patient they do not have current HCV infection and require no antiviral treatment 1
- No further testing is typically necessary 1
When to Consider Repeat Testing
HCV RNA testing should be repeated only if: 1
- The patient has ongoing HCV infection risk (active injection drug use, high-risk sexual practices, occupational exposures)
- There is high clinical suspicion for recent infection (acute hepatitis presentation, known recent exposure)
- The patient is immunocompromised (may have delayed seroconversion or false-negative RNA in early infection)
If repeat testing is warranted, recheck HCV RNA at 12 and 24 weeks to confirm definitive clearance 2
Optional Confirmatory Testing
If you or the patient wish to distinguish between resolved infection versus false-positive antibody:
- Repeat HCV antibody testing with a different assay 1
- A false-positive result typically does not occur with two different assays
- This distinction has no clinical impact on management but may provide reassurance
Key Pitfalls to Avoid
- Do not initiate antiviral therapy based on antibody positivity alone—HCV RNA must be detectable 1
- Do not assume ongoing infection—approximately 15-25% of acute HCV infections spontaneously clear, and antibodies persist after clearance
- Do not order unnecessary repeat testing unless specific risk factors exist 1
- Ensure the RNA assay used had adequate sensitivity (detection limit ≤25 IU/mL) 1—though most modern assays meet this threshold
Why This Matters
The AASLD-IDSA guidelines explicitly state that quantitative HCV RNA testing is required prior to initiating antiviral therapy to confirm active viremia 1. Treatment recommendations apply only to persons with current HCV infection, defined by detectable HCV RNA 1. The presence of antibodies alone, without viremia, does not meet criteria for treatment and reflects either past exposure with clearance or false-positive serology.